SENP1 participates in the dynamic regulation of Elk-1 SUMOylation by Witty, James et al.
Biochem. J. (2010) 428, 247–254 (Printed in Great Britain) doi:10.1042/BJ20091948 247
SENP1 participates in the dynamic regulation of Elk-1 SUMOylation
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The modiﬁcation of proteins with SUMO (small ubiquitin-
related modiﬁer) plays an important role in determining their
functional properties. Importantly though, SUMOylation is a
highlydynamicprocessenablingtransientresponsestobeelicited.
This dynamism is controlled by two competing conjugating
and deconjugating activities. The latter activity is mediated
by the SENP [SUMO1/sentrin/SMT3 (suppressor of mif two
3 homologue 1)-speciﬁc peptidase] family of SUMO-speciﬁc
proteases. The transcription factor Elk-1 [ETS (E twenty-six)-
like 1] undergoes rapid de-SUMOylation following cellular
stimulation with growth factors, and this contributes to its
conversion from a SUMO-dependent repressor into a potent
transcriptional activator. In the present study we demonstrate
an important role for SENP1 in the de-SUMOylation of
Elk-1, and therefore an integral role in determining the Elk-1-
dependent transcriptional programme. Among the SENPs, Elk-1
preferentially forms a complex with SENP1. This preferential
binding is reﬂected by the higher efﬁciency of SENP1 in
promoting Elk-1 transactivation. Moreover, depletion of SENP1
causes a reciprocal effect and reduces the transactivation
properties of Elk-1. Partial redundancy of function with SENP2
is revealed by combinatorial knockdown studies. Importantly,
depletion of SENP1 also reduces the activation of the Elk-1 target
gene c-FOS. Taken together, these results therefore reveal an
important role for SENP1 in the regulation of Elk-1-mediated
gene expression in response to mitogenic signalling cues.
Key words: ETS (E twenty-six)-like 1 (Elk-1), SUMO1/
sentrin/SMT3 (suppressor of mif two 3 homologue 1)-speciﬁc
peptidase (SENP), small ubiquitin-related modiﬁer (SUMO),
transcription.
INTRODUCTION
Protein SUMOylation is being increasingly recognized as an
important post-translational modiﬁcation. Both cytoplasmic and
nuclear proteins have been shown to be SUMO (small ubiquitin-
related modiﬁer) substrates, but the majority of substrates
fall into the latter class, with one major function of SUMO
being in transcriptional control (reviewed in [1–3]). Importantly,
protein SUMOylation is a dynamic process. SUMO is added to
proteins through the action of an enzymatic cascade involving
an E1 SUMO-activating enzyme, and the E2 SUMO-conjugating
enzyme Ubc9 which transfers the SUMO to substrates. In several
cases, E3 ligases can act as molecular bridges to facilitate the
action of Ubc9 and promote substrate SUMOylation (reviewed
in [2,4]). Conversely, SUMOylation can be reversed through the
activityofSENPs[SUMO1/sentrin/SMT3(suppressorofmiftwo
3 homologue 1)-speciﬁc peptidases] which cleave SUMO from
substrates (reviewed in [5,6]). There are currently six known
SENPs in humans, which are thought to act, in part, in distinct
subnuclear structures with SENP1 and 2 localized to the nuclear
pore complex and nucleoplasm, whereas SENP3 and SENP5
are localized to the nucleolus, at least under normal conditions
(reviewed in [5,6]).
Protein SUMOylation can be controlled through the activity
of protein kinase cascades in response to extracellular signals
(reviewed in [7]). For example, HSF-1 (heat-shock factor-
1) SUMOylation status is enhanced following heat-shock-
mediated phosphorylation [8]. Similarly, SUMOylation is
promoted in several other proteins following signal-dependent
phosphorylation (reviewed in [9,10]). In contrast, following
mitogen-dependent activation of the ERK (extracellular-signal-
regulated kinase) MAPK (mitogen-activated protein kinase)
pathway, reduced SUMOylation of the transcription factor Elk-1
[ETS (E twenty-six)-like 1] occurs [11]. De-SUMOylation of
Elk-1 is a component of the transcriptional activation process
that is orchestrated by this transcription factor in response
to ERK pathway signalling. In contrast, anisomycin-dependent
activation of the p38 MAPK cascade does not result in Elk-1
de-SUMOylation, although the activation component of the
signallingpathwaystilloccurs[12].ThusElk-1de-SUMOylation
is an important mechanism that dictates the outcome of MAPK
signalling through Elk-1 and its target genes, and helps set the
amplitude of the resulting transcriptional response.
In the present study, we further investigated how mitogenic
signalling promotes Elk-1 de-SUMOylation and hence the
functional outcome in terms of target gene expression. We sought
to identify which SENP is involved in the de-SUMOylation
process. Through a combination of overexpression and loss-
of-function approaches, we have identiﬁed SENP1 as the
predominant SENP acting on Elk-1, and hence placing SENP1
as a key player in determining the transcriptional outcomes to
mitogenic signalling.
MATERIALS AND METHODS
Plasmid constructs
The following plasmids were used in mammalian cell
transfections. pRL-TK-Renilla (Promega; TK is thymidine
kinase),pG5-E1B-Luc,pAS1561[encodingGAL–Elk(1–428)
WT;
WT is wild-type], pAS2058 [encoding GAL–Elk(1–428)
K2R],
pAS383 [encoding Flag-His-tagged Elk(1–428)
WT] [11] and
pCDNA3-HA-SUMO-2 (HA is haemagglutinin) [13] have been
described previously.
pAS1138 (pCDNA3-FlagB-SENP1
WT), pAS1140 (pCDNA3-
FlagB-SENP2
WT), pAS1139 (pCDNA3-FlagB-SENP1
C602S)a n d
Abbreviations used: Elk-1, ETS (E twenty-six)-like 1; ERK, extracellular-signal-regulated kinase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase;
GST, glutathione transferase; HA, haemagglutinin; HDAC, histone deacetylase; HEK, human embryonic kidney; MAPK, mitogen-activated protein kinase;
RT, reverse transcription; SENP, SUMO1/sentrin/SMT3 (suppressor of mif two 3 homologue 1)-speciﬁc peptidase; siRNA, small interfering RNA; SUMO,
small ubiquitin-related modiﬁer; WT, wild-type.
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pAS1141 (pCDNA3-FlagB-SENP2
C547S) were constructed by
inserting EcoRI-NotI fragments from pAS1134, pAS1136,
pAS1135 and pAS1137 respectively, into pCDNA3-FlagB
(pAS2236). pAS1134, pAS1135, pAS1136 and pAS1137 were
constructed by inserting EcoRI-SalI fragments from pCMV-Flag-
SENP1
WT, pCMV-Flag-SENP1
C602S, pCMV-Flag-SENP2
WT and
pCMV-Flag-SENP2
C547S respectively (WT versions were kindly
provided by Professor Edward Yeh, Department of Cardiology,
TheUniversityofTexas,M.D.AndersonCancerCenter,Houston,
TX, U.S.A.; [14]) into the same sites in pGEX4T3. pCMV-
Flag-SENP1
C602S and pCMV-Flag-SENP2
C547S were constructed
using QuikChange® mutagensis (Stratagene) using the template
and the primer pair combinations: pCMV-Flag-SENP1
WT and
ADS2518/2519 and pCMV-Flag-SENP2
WT and ADS2520/2521
respectively. pAS1142 (pCDNA3-FlagC-SENP3
WT)a n d
pAS1143 (pCDNA3-FlagC-SENP3
C532S) were constructed by
inserting BamHI-XhoI fragments from pCDNA3-RGS-SENP3
WT
and pCDNA3-RGS-SENP3
C532S respectively (kindly provided by
Professor Edward Yeh; [15]), into pCDNA3-FlagC (pAS2237).
Forbacterialexpression,GST(glutathionetransferase;pAS2751)
and GST–Elk-1(205–428) (pAS407) were used [16].
Tissue culture, cell transfections, siRNA (small interfering RNA),
reporter gene assays and RT (reverse transcription)–PCR
HEK (human embryonic kidney)-293T and HeLa cells were
grown in DMEM (Dulbecco’s modiﬁed Eagle’s medium)
supplemented with 10% FBS (fetal bovine serum). Trans-
fections were performed using Polyfect
TM (Qiagen) according
to the manufacturer’s instructions. Where indicated, cells were
serum-starved for 24 h, then treated with PMA (10 nM) or
anisomycin (250 ng/ml) prior to luciferase assays (6 h) or RT–
PCR analysis (40 min).
TransfectionsofsiRNAs wereachievedusingLipofectamine
TM
siRNAMax (Invitrogen) according to the manufacturer’s in-
structions. ON-TARGETplus SMARTpool siRNAs (Dharmacon)
against SENP1, SENP2, SENP3 and GAPDH (glyceraldehyde-3-
phosphate dehydrogenase) were used.
For reporter gene assays, typically 0.25 μgo fr e p o r t e rp l a s m i d
a n d5 0n go fp R L - T K - Renilla were co-transfected with 0.1–
1 μg of expression plasmids. Cell extracts were prepared and
equal amounts of protein were used in luciferase assays using the
dual-luciferase kit (Promega). Data were normalized against the
expression of the Renilla luciferase.
Real-time RT–PCR was carried out using the QuantiTect
SYBR Green RT–PCR mix (Qiagen). All data were normalized
to the levels of 18S rRNA. The following primer pairs were
used for RT–PCR experiments. 18S RNA, ADS4005 (5
 -TC-
AAGAACGAAAGTCGGAGGTT-3
 ) and ADS4006 (5
 -GGAC-
ATCTAAGGGCATCACAG-3
 ); c-FOS, ADS1690 (5
 -AGAA-
TCCGAAGGGAAAGGAA-3
 ) and ADS1691 (5
 -CTTCTCC-
TTCAGCAGGTTGG-3
 ); SENP1, ADS2502 (5
 -TTAACTA-
ACCAGGAACAGCTG-3
 ) and ADS2503 (5
 -GAGTCTGA-
TCCTTCAGATTGTG-3
 ); SENP2, ADS2506 (5
 -GAACTTAC-
AGAGGACATGGA-3
 ) and ADS2507 (5
 -CTGAATACATG-
AAGTGCTGG-3
 ); SENP3, ADS2512 (5
 -GAGCATCTT-
GGACGAATTCC-3
 ) and ADS2513 (5
 -GTTCATCACCTG-
GTCATTGAG-3
 ). Three independent RT–PCRs were run on
the same RNA samples to reduce variability and produce a mean
value for each data point.
In vivo SUMOylation and in vitro de-SUMOylation assays
In vivo SUMOylation of overexpressed Elk-1 was detected by
co-transfection of His-tagged Elk-1 and HA-tagged SUMO-2
proteins, followed by puriﬁcation of the conjugates under
denaturing conditions as described previously [11].
In vitro de-SUMOylation assays were performed using
SUMO-modiﬁed recombinant GST–Elk-1 fusion proteins and
immunoprecipitated FLAG-tagged SENP proteins. To prepare
SUMOylated recombinant Elk-1, a reconstituted SUMOylation
system in Escherichia coli was used [18]. To prepare SENPs,
HEK-293T cells were transfected with 30 μg of FLAG–SENP1
DNA. At 48 h post-transfection, cells were resuspended in Buffer
II [25 mM Tris/HCl (pH 8), 150 mM NaCl, 0.1% Tween 20,
2 mM DTT (dithiothreitol) and Complete
TM protease inhibitors
(Roche), diluted 1:100] and lysed by passing them trough a
25-gauge needle. The SENP protein was puriﬁed using an anti-
FLAG antibody conjugated to agarose beads. Beads containing
the protein were washed twice in Buffer II containing 1 M NaCl
and twice in Buffer II. Protein was eluted by adding FLAG
peptide. Assays were carried out as described previously [18].
SUMOylated Elk-1 from 50 ml cultures was puriﬁed and kept
bound to the GSH–agarose. Reactions (50 μl volume) in Buffer
II were incubated at 37◦C, and shaken at 700 rev./min for the
times indicated. The samples were spun down, the supernatant
was removed and proteins were eluted by adding 1×SDS/PAGE
loading buffer. Gels were stained overnight using SYPRO-Ruby
and visualized using a Bio-Rad gel doc.
GST-pulldown assays
GST-pulldown assays were carried put using recombinant GST–
Elk-1 and cell lysates of HEK-293T cells transfected with
constructs encoding each of the catalytically dead FLAG-tagged
SENP1–3 enzymes, essentially as described previously [19].
Immunoprecipitation and Western blot analysis
Westernblottingandimmunoprecipitationswerecarriedoutusing
SuperSignal
TM West Pico or Dura (Pierce) chemiluminescent
substrates with the primary antibodies anti-FLAG (Sigma),
anti-Elk-1 (Santa Cruz Biotechnology) or anti-HA (Roche)
according to the manufacturer’s instructions. Data were analysed
usingQuantity-Onesoftware(Bio-Rad).Co-immunoprecipitation
assays were performed in 50 mM potassium phosphate (pH 7.8),
0.1% Triton X-100, 150 mM NaCl, 10 nM N-ethylmaleimide, 10
nM E64 (Sigma) and 1:100 protease inhibitor cocktail (Roche),
followed by three washes in the same solution.
RESULTS
Elk-1 is preferentially activated by SENP1
Elk-1 is SUMO-modiﬁed and this dampens down its
transactivation activity and promotes active transcriptional
repression. SUMOylation is lost during the transition to a
transcriptional-activating state [11]. To begin to probe which
SUMO protease(s) is involved in reversing Elk-1 SUMOylation
we compared the abilities of different SUMO proteases (SENPs)
toactivateElk-1throughde-SUMOylation.Weﬁrstcomparedthe
expression levels of the SENPs. SENP1 and 3 were expressed at
similar levels, with SENP2 being expressed to a slightly lesser
extent (Figure 1B). Next, we compared the abilities of the SENPs
to activate a GAL–Elk-1(1–428) fusion protein in a luciferase
reporter assay (Figure 1A). This fusion protein is regulated by
the SUMO pathway in an analogous manner to full-length Elk-1
[11,20]. SENP1 had the biggest effect on Elk-1 activation,
whereas SENP3 barely affected Elk-1 activity; SENP2 had an
intermediary effect (Figure 1C). Owing to the reduced expression
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Figure 1 SENP1 preferentially activates Elk-1
(A)SchematicdiagramoftheGAL-drivenreportersystemusedtoassayElk-1-mediatedtransactivation.(B)Immunoprecipitation/WesternblotanalysisoftheexpressionoftheindicatedFLAG-tagged
SENP constructs. HEK-293T cells were transfected with different SENP expression vectors followed by immunoprecipitation with an anti-FLAG antibody and detection by Western blot analysis with
the same antibody. The * represents a band corresponding to the antibody heavy chain. (C and D) Luciferase reporter analysis of the activity of GAL–Elk-1(1–428) constructs in the presence of
co-transfected SENP expression constructs. (C) Wild-type (black bars) and K230R/K249R(K2R) mutant (grey bars) Elk-1 constructs were transfected in the absence and presence of the indicated
SENP constructs. (D) Wild-type GAL–Elk-1 constructs were transfected in the presence of increasing amounts (0 ng, 125 ng, 250 ng, 500 ng and 1 μg) of the indicated SENP constructs. (E)
Wild-type GAL–Elk-1 constructs were transfected in the presence of 1 μg of the indicated WT (black bars) or catalytically dead (mut; grey bars) SENP constructs. In all cases data are presented
relative to the activity of either WT or K2R versions of GAL–Elk-1(1–428) in the presence of the control empty vector (taken as 1). Data are the average of two independent experiments, each with
triplicate samples.
levels of SENP2, we performed a dose–response experiment to
compare the ability of SENP1 and SENP2 to activate Elk-1.
However, even at 10-fold higher levels, SENP2 still activated
Elk-1 to a lesser extent than SENP1 (Figure 1D, compare column
2, black bars with column 6, grey bars).
The effects of the SENPs could be indirect and/or independent
of their SUMO-deconjugating activities. We therefore ﬁrst
established whether the Elk-1 SUMOylation sites are required for
SENP-mediated activation. Again, we used a luciferase reporter
assay but, instead of the WT protein, we tested GAL–Elk-1(1–
428)(K2R), which lacks the two major SUMOylation sites at
Lys
230 andLys
249 [11].IncomparisonwithWTElk-1,Elk-1(K2R)
showed much reduced activation by the SENPs (Figure 1C),
consistent with a role for SENPs in de-SUMOylating Elk-1.
Conversely, we tested the activity of catalytically inactive mutant
versionsoftheSENPswhichhadtheiractive-sitecysteineresidues
mutated. The ability of SENP1 to activate Elk-1 was much
reduced, and a similar effect was seen on the smaller activation
caused by SENP3 (Figure 1E). In contrast, the mutant version of
SENP2 was able to activate Elk-1 to a similar extent as the WT
version (Figure 1E), demonstrating that the activating effect of
SENP2 on Elk-1 occurs by a mechanism that is independent from
its SUMO-deconjugating activity.
Taken together, these results demonstrate that SENP1 is the
most efﬁcient SUMO protease acting on Elk-1, and that SENP3
has little effect on Elk-1. SENP2 has an intermediate effect,
but its ability to activate Elk-1 is independent from its SUMO-
deconjugating activity.
SENP1 binds to Elk-1
As SENP1 was established as the most efﬁcient SUMO
protease acting on Elk-1, we investigated whether we could
detect complexes between these two proteins. Initial attempts
at detecting interactions between Elk-1 and WT SENP1 were
unsuccessful, either at endogenous or overexpressed levels. We
reasoned that this might be due to the transient interactions
between the enzymatic SENPs and their substrate Elk-1.
Therefore, to potentially trap these interactions, we used
a catalytically dead version of SENP1 (SENP1
CS)i nc o -
immunoprecipitation assays. In contrast with WT SENP1 where
no complex could be detected, a complex detected between
Elk-1 and the mutant SENP1
CS (Figure 2A, lanes 2 and 3).
Next, we compared the ability of SENP1
CS and the equivalent
catalytically dead mutant version of SENP2 (SENP2
CS)t o
bind Elk-1. Preferential binding of SENP1 was observed in a
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Figure 2 Elk-1 interacts with SENP1
(A and B) Co-immunopreciptation analysis of Elk-1(1–428) and SENPs. (A) Elk-1 was transfected in the absence and presence of the indicated WT and catalytically inactive (CS) versions of
FLAG-taggedSENP1.FollowingimmunoprecipitationofElk-1(IP),boundSENPsweredetectedbyimmunoblotting(IB)withananti-FLAGantibody.Immunoprecipitatedproteinsareshowninthetop
two panels and input proteins are shown in the bottom two panels. (B) Elk-1 was transfected in the absence and presence of the indicated catalytically inactive (CS) versions of FLAG-tagged SENPs.
Following immunoprecipitation of Elk-1 (IP), bound SENPs were detected by immunoblotting (IB) with an anti-FLAG antibody. Immunoprecipitated proteins are shown in the top two panels and
input proteinsin thebottom panel.* Indicates non-speciﬁccross-reacting bandsin the IP samples. (C) GST-pulldown analysis ofGST–Elk-1(205–428)binding to SENPs.Theindicated catalytically
inactive SENPs were expressed in HEK-293T cells, the lysates bound to recombinant GST or GST–Elk-1 and were detected by IB with an anti-FLAG antibody (top panel). A Coomassie-Blue-stained
gel of the input bait proteins is shown in the bottom panel.
co-immunoprecipitation assay (Figure 2B). To further probe the
speciﬁcity of these interactions we performed GST-pulldown
assays with recombinant GST–Elk-1 and HEK-293T cell lysates
containing each of the catalytically dead SENP1–3 enzymes.
Preferential interactions were observed with SENP1 (Figure 2C).
Collectively, these results demonstrate that SENP1 can form
complexes with Elk-1 and this interaction appears to be speciﬁc
among the SENPs.
SENP1 de-SUMOylates Elk-1
The ability of SENP1 to activate Elk-1 in a SUMO-dependent
manner suggests that SENP1 can de-SUMOylate Elk-1. To prove
that this is the case, we performed in vitro de-SUMOylation
assays using recombinant SUMO-modiﬁed Elk-1 and FLAG-
tagged SENP1 or SENP3 immunoprecipitated from HEK-293T
cells. Elk-1 was modiﬁed by SUMO using an E. coli system
containing a reconstituted SUMO pathway (Figure 3A; [18]), and
equalamountsofimmunoprecipitatedSENP1andSENP3(Figure
3B)wereincubatedwiththisrecombinantprotein.Theadditionof
SENP1resultedinlossofSUMOconjugationtoElk-1(Figure3C,
lanes4–6),demonstratingthatElk-1isadirecttargetoftheSUMO
proteolytic activity of SENP1. In contrast, little de-SUMOylation
was seen upon incubation with SENP3 (Figure 3C, lanes 7–9).
Thus, in agreement with the reporter and binding assays, SENP1
and SENP3 show different activities towards Elk-1, with SENP1
more efﬁciently de-SUMOylating Elk-1 in vitro.
Endogenous SENP1 is important for Elk-1 activation
We have established that, among SENPs, Elk-1 is preferentially
activated by overexpressed SENP1 and binds speciﬁcally to
SENP1. However, to determine whether endogenous SENP1 is
important for Elk-1 activation, we compared the effect of siRNA-
mediated depletion of SENP1 with depletion of other SENPs on
Elk-1 activity. First we determined the efﬁcacy and speciﬁcity of
each siRNA in depleting SENP mRNA levels. Each of the siRNA
pools speciﬁcally depleted the corresponding SENP mRNA with
high efﬁciency, with negligible effects on the other SENPs
(Figure 4B), thereby demonstrating their utility for subsequent
Figure 3 SENP1 de-SUMOylates Elk-1 in vitro
(A)ACoomassie-Blue-stainedgelshowingthenon-SUMOylatedandSUMOylatedrecombinant
GST–Elk-1 fusion proteins. (B) Western blot analysis of FLAG-tagged SENP1 and SENP3
puriﬁed by immunoprecipitation from transfected HEK-293T cells. The broken line indicates
where irrelevant lanes were removed. (C) SUMOylated recombinant GST–Elk-1(205–428) was
incubated in the presence or absence of FLAG-tagged SENP1 or SENP3 for the times indicated
and samples were detected by SYPRO-Ruby staining after SDS/PAGE. The positions of the
recombinant Elk-1 protein and its SUMOylated forms are indicated. * Indicates the position of
a co-purifying contaminant.
functional assays. Next, we compared the activity of Elk-1 in
a luciferase reporter assay under serum-starved conditions or
upon PMA treatment. PMA treatment leads to activation of the
ERK pathway and loss of SUMO on Elk-1 and hence loss of its
repressive properties (Figure 4A; [11]). In the absence of PMA, a
10% reduction in Elk-1 activity was observed following SENP1
depletion, but little effect was seen upon depleting the other
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Figure 4 Depletion of SENP1 decreases the transactivation capacity of Elk-1
(A) Schematic diagram of the GAL-driven reporter system used to assay Elk-1-mediated transactivation following ERK pathway activation. (B) RT–PCR analysis of the expression of the indicated
SENPs in HeLa cells in the presence of control siRNAs or siRNA duplexes directed against the SENPs indicated. Data are representative of two independent experiments and are the average of
two samples, presented relative to the transcript levels in the presence of control siRNA duplexes (taken as 1). (C–E) Luciferase reporter analysis of the activity of GAL–Elk-1(1–428) constructs in
HEK-293T cells in the presence of co-transfected siRNA duplexes against SENPs. All data are the average of two experiments carried out in duplicate. Note that the axis does not begin at zero to
emphasize the changes we observe. (C and D) Individual siRNA duplexes (25 pmol) were transfected in the presence of either WT (C) or mutant K230R/K249R(K2R) (D) forms of Elk-1. Cells were
either untreated (grey bars) or treated with PMA for 6 h (black bars). (E) Cells were treated with PMA after transfection with vectors encoding WT (grey bars) or mutant (K2R) (black bars) versions of
GAL–Elk-1(1–428) and with siRNA targeting SENP1 (12.5 pmol), and the additional siRNA constructs (12.5 pmol) against different indicated SENPs.
SENPs (Figure 4C, grey bars). This effect was even more
pronounced in the presence of PMA, with >20% reduction in
Elk-1 activity seen following SENP1 depletion. Again, depletion
oftheotherSENPshadanegligibleeffect(Figure4C,blackbars).
We also probed the effect of SENP depletion on the activity of the
Elk-1(K2R) mutant protein that could not be SUMO-modiﬁed. In
contrast with the effects seen with the WT protein, depletion of
anyoneoftheSENPshadnoeffectontheactivityofElk-1(K2R),
either in the presence or absence of PMA treatment (Figure 4D).
This is consistent with a role for SENP1 in directly acting to
de-SUMOylate Elk-1.
Although signiﬁcant, the depletion of SENP1 caused relatively
small changes in the activity of Elk-1. This could be
due to functional redundancy whereby, in the absence of
SENP1, another SENP can at least partially substitute for its
activity. To test such a possibility, a combinatorial knockdown
approach was undertaken. SENP1 siRNAs were used in
combination with either SENP2 or SENP3 siRNAs. Again,
SENP1 depletion caused a reduction in the activity of Elk-1
following PMA treatment, but this effect was ampliﬁed by the
simultaneous depletion of SENP2, with Elk-1 activity reduced
by nearly 40% (Figure 4E, grey bars). In contrast, co-depletion
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Figure 5 Depletion of SENP1 decreases the activation of the Elk-1 target gene c-FOS
(A)Schematicdiagramshowingthedifferentmoleculareventsoccurringonthec-FOS promoterafterPMA(SUMOloss)oranisomycin(SUMOretention)stimulation.Inbothcases,c-FOS promoter
activation is still observed. SRE, serum-response element. (B) Western blot analysis of Elk-1 SUMOylation levels. HEK-293T cells were transfected with expression vectors for His-FLAG-tagged
Elk-1 andHA-tagged SUMO-2, andHis-tagged Elk-1 waspulleddown(PD) from lysates from HEK-293Tcells treated with PMA or anisomycinfor 40min. TotalandSUMOylated Elk-1 were detected
by immunoblotting (IB) with anti-FLAG and anti-HA antibodies respectively. (C–F) RT–PCR analysis of the expression of c-FOS in HeLa cells in the presence of control GAPDH siRNAs or siRNA
duplexes directed against the SENPs indicated. Either an siRNA duplex against a single SENP (25 pmol) or two siRNA duplexes against distinct SENPs (12.5 pmol each) were transfected and cells
were either serum-starved (grey bars) or treated with PMA (C and E) or anisomycin (D and F) for 40 min (black bars). Data are the average of duplicate samples and are presented relative to the
transcript levels in serum-starved cells in the presence of control GAPDH siRNA duplexes (taken as 1).
of SENP3 did not further enhance the activity of Elk-1,
suggesting that, at the level of functional redundancy, there is
still speciﬁcity of action. Again, neither the depletion of SENP1
alone nor in combination with other SENPs led to a reduction in
the activity of the Elk-1(K2R) mutant (Figure 4E, black bars).
Taken together these results therefore demonstrate that SENP1
is the predominant SENP acting to promote Elk-1 activation in a
SUMO-dependentmanner,althoughthereisadegreeoffunctional
redundancy with SENP2.
SENP1 plays a role in Elk-1 target gene activation in response to
mitogenic signalling
One of the best characterized Elk-1 target genes is c-FOS. Elk-1
orchestratestheactivationofc-FOSinresponsetobothmitogenic
and stress signals, such as PMA and anisomycin. However,
while PMA treatment leads to loss of SUMOylation, anisomycin
treatment does not (Figure 5A; [12]), although both treatments
lead to Elk-1 phosphorylation and c-FOS activation.We therefore
probed the roles of SENPs in signal-dependent c-FOS activation.
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FirstwedemonstratedthatPMAandanisomycinhadthepredicted
effects on Elk-1 SUMOylation, with only PMA promoting
SUMO loss (Figure 5B). Next, we depleted SENP1, SENP2 or
SENP3, and investigated c-FOS activation. The loss of SENP2 or
SENP3 had little effect, but SENP1 loss caused a reduction in
c-FOS activation following PMA treatment (Figure 5D). In
contrast, little reduction was seen in c-FOS activation by ani-
somycin upon depletion of individual SENPs, including SENP1
(Figure 5D).
Studies using reporter gene analysis suggested that a degree of
functional redundancy exists between SENP1 and SENP2 which
mightmasktheeffectofSENP1depletion(Figure4).Wetherefore
compared the effect of depleting both SENP1 and SENP2 with
depletion of SENP1 alone. Again, SENP1 depletion caused a
reduction in c-FOS activation following PMA stimulation, but
this effect was enhanced upon co-depletion of SENP2 (Figure
5E). In contrast, anisomycin-dependent c-FOS activation was
unaffected by SENP1 depletion, either alone or in combination
with SENP2 (Figure 5F). The lack of involvement of SENPs in
c-FOS activation by anisomycin is consistent with the lack of
requirement for SUMO loss in the activation of Elk-1 by this
treatment.
These data therefore demonstrate that SENP1 is the
predominantSENPactingtopromoteactivationoftheElk-1target
gene c-FOS following mitogenic stimulation and, consistent with
thereportergeneassays,thereisadegreeoffunctionalredundancy
with SENP2. In contrast, under signalling conditions where Elk-1
SUMOylation is not required (i.e. anisomycin treatment), SENP1
is not required for c-FOS induction.
DISCUSSION
SUMOylation plays an important physiological role in
determining the outcome of numerous processes in the cell.
Importantly, SUMOylation is a dynamic process, enabling
transient responses to be elicited, to processes such as cellular
signalling events (reviewed in [7,21]). However, in most cases,
it is unclear how SUMO conjugation is either promoted or
subsequently lost in response to signalling cues. SUMO loss
is promoted by the SENPs (reviewed in [5,6]). In the present
study, we have focussed on Elk-1 and investigated the roles of
SENPsinthede-SUMOylationprocess.Elk-1makesanattractive
model as SUMOylation promotes its transcriptional-repressive
propertiesand,dependingonthestimulusreceived,SUMOylation
is either retained (upon stress signalling) or lost (upon mitogenic
signalling). In the present study, we identiﬁed SENP1 as a key
player in the loss of SUMO from Elk-1 in response to ERK
pathway signalling (Figure 6).
Several lines of evidence establish SENP1 as the predominant
SENP involved in Elk-1 de-SUMOylation: (i) SENP1 is the most
efﬁcient activator of Elk-1 in overexpression studies, (ii) Elk-1
binds preferentially to SENP1, (iii) SUMO-modiﬁed Elk-1 is
a substrate for SENP1 in vitro, (iv) SENP1 depletion reduces
the activation of Elk-1 by PMA, and (v) SENP1 depletion
reduces the activation of the Elk-1 target gene c-FOS following
mitogenic stimulation. Importantly, we compared the effect of
several SENPs in each of the assays to demonstrate the speciﬁcity
of SENP1 action. Moreover, we also veriﬁed that the effect of
SENP1 was direct by determining the SUMO-dependence of its
effects. SENP1-dependent activation of Elk-1 depended on its
catalytic activity and the presence of SUMOylation sites in Elk-
1 (Figure 1). Similarly, depletion of SENP1 only had an effect
on Elk-1 activity when its SUMOylation sites were intact (Fig-
ure 4). Finally, SENP1 depletion only affected c-FOS activation
Figure 6 Model for the role of SENP1 in Elk-1 regulation
IntheabsenceofERKpathwaysignalling,Elk-1iskeptinarepressivestatebySUMO-mediated
HDAC-2 recruitment. Following ERK activation, Elk-1 is de-SUMOylated, leading to enhanced
transactivation capacity, and SENP1 plays a pivotal role in this process. SRE, serum-response
element.
under signalling conditions where SUMO loss is known to occur
(Figure 5).
There are six known SENPs in humans and it is possible that
somedegreeoffunctionalredundancyoccurs.Inthepresentstudy,
we only tested the effects of three different SENPs, although
several assays were performed to test the role of SENP5, but
this had little effect on the activity of Elk-1 or its target gene
c-FOS (results not shown). It therefore remains possible that
the additional SENPs SENP6 and SENP7 play a role in Elk-1
activation, maybe in a redundant manner. Nevertheless, it is clear
that SENP1 plays a predominant role in Elk-1 de-SUMOylation.
WedohoweverobservefunctionalredundancyinSENP-depletion
assays where SENP2 speciﬁcally substitutes for SENP1 upon
SENP loss (Figures 4 and 5). In this scenario though, the primary
role of SENP1 is probably dictated due to its stronger binding to
Elk-1 than SENP2 (Figure 2), thereby occluding SENP2 access
to the SUMOylation sites. Only when SENP1 is lost will SENP2
be able to work on Elk-1.
Binding experiments demonstrated a speciﬁc interaction
between SENP1 and Elk-1 (Figure 2). However, to perform such
experiments in vivo, we had to use catalytically inactive versions
of SENPs. The rationale behind this was that such mutants would
stay associated for longer rather than merely transiently binding
and dissociating following SUMO cleavage. Precedents for such
behaviour exists in other enzyme–substrate systems where, for
example,p38MAPKbindingtoMEF2(myocyteenhancerfactor-
2) could only be strongly detected using catalytically dead
p38 MAPK [22]. Unfortunately, this observation precluded the
possibility of detecting interactions between endogenous SENP1
andElk-1,andprobablywillmakeanysuchsubstrate–SENPpairs
difﬁcult to detect at endogenous levels.
While SENP1 is the predominant SENP involved,
overexpression of SENPs has various effects on Elk-1 activity
(Figure 1). For example, SENP2 and SENP3 caused smaller, yet
signiﬁcant, increases in Elk-1 activity. This might merely be due
to overexpression and displacement of endogenous SENP1, but
might also have an important role. For example, SENP3 activates
Elk-1 to a small extent, and this activation might be through p300
asthiswasrecentlyshowntobeaphysiologicallyrelevantSENP–
substrate pairing [23]. In contrast, SENP2 can activate Elk-1, but
this activation appears to be largely independent from its de-
SUMOylation function as the catalytically dead version activates
Elk-1 as efﬁciently as the WT version (Figure 2E). It is not
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clear what this de-SUMOylation-independent activity of SENP2
might be, although a similar phenomenon has previously been
described for the SENP2-dependent activation of c-Jun [24]. The
observation that SENP2 functions in a manner independent from
its de-SUMOylation activity apparently contradicts its ability
to substitute for SENP1 in regulating Elk-1 in a SUMO-site-
dependent manner. However, it is possible that, in the case of
overexpression, additional effects are triggered which would not
been seen at endogenous levels, therefore interpretation of the
results of these type of overexpression assays need to be treated
with caution. Nevertheless, the assays do demonstrate a more
potent activity of SENP1 towards Elk-1 as a SUMO protease,
especiallyconsideringthealternativemodeofactionofSENP2in
these overexpression assays. Knockdown studies further support
the role of SENP1 and more realistically delineate the potential
functional redundancy of SENP2 at endogenous levels where its
effects are, at least in part, elicited through its SUMO-protease
activity.
Initially, it was thought that de-SUMOylation would be a
fairly non-speciﬁc process. However, our demonstration that
Elk-1 is preferentially targeted by SENP1 provides another
memberofagrowinglistofspeciﬁcSENP–substrateinteractions.
Notable examples include SENP3 and p300 in response to mild
oxidative stress [23], and the speciﬁc role of SENP1 in targeting
HIF-1α (hypoxia-inducible factor-1α) [25] and HDAC (histone
deacetylase)-1 [14]. At least part of the functional speciﬁcity
of SENPs appears to result in their subnuclear localization,
with SENP3 being localized to the nucleolus and thereby de-
SUMOylating nucleolar substrates, such as nucleophosmin [26],
although recent results demonstrate that nucleolar SENPs, such
as SENP3, can be released into the nucleoplasm following mild
oxidative stress [23]. In contrast, SENP1 and SENP2 are thought
to be the major SENPs in the nucleoplasm, which is consistent
with a role for SENP1 in controlling Elk-1 activity. It appears
likely therefore that each SENP will have a speciﬁc spectrum
of substrates, although some degree of functional redundancy is
probablybuiltinasapotentialfailsafemechanismandsubcellular
localization will, to some degree, dictate the availability of
substrates. It is, however, clear that the SENPs play a positive role
in determining the dynamics and functional outcome of protein
SUMOylation.
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